Señales en vivo de SYRS | Maximiza tus Ganancias con Getagraph.com

VENDER 116336 min ago

@ $7.03

Emitido: 14 feb 2024 @ 09:30

Retorno: -27.03%

Señal anterior: feb 13 - 09:30

Señal anterior: Comprar

Retorno: 3.84 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines...

Stats
Volumen de hoy	54 354.00
Volumen promedio	206 232
Capitalización de mercado	137.12M
EPS	$0 ( 2024-03-27 )
Próxima fecha de ganancias	( $-0.890 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.880
ATR14	$0.0190 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Roth David	Sell	10 451	Common Stock
2024-03-31	Stephens Kristin	Buy	11 666	Common Stock
2024-04-01	Stephens Kristin	Sell	4 218	Common Stock
2024-03-31	Stephens Kristin	Sell	11 666	Restricted Stock Units
2024-03-31	Stephens Kristin	Buy	2 000	Common Stock

INSIDER POWER
54.57
Last 100 transactions
Buy: 2 824 203 \| Sell: 497 307

Volumen Correlación

Largo: -0.02 (neutral)

Corto: 0.57 (weak)

Signal:(48.562) Neutral

Syros Pharmaceuticals Inc Correlación

10 Correlaciones Más Positivas
BOTJ	0.855
NEPH	0.851
BSBK	0.846
CABA	0.834
CCOI	0.824
Z	0.821
ZG	0.817
FOLD	0.814
HUBG	0.812
PANL	0.808

10 Correlaciones Más Negativas
RMRM	-0.866
SIVBP	-0.845

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Syros Pharmaceuticals Inc Correlación - Moneda/Commodity

0.07
( neutral )

0.66
( moderate )

0.00
( neutral )

0.07
( neutral )

0.21
( neutral )

Syros Pharmaceuticals Inc Finanzas

Annual	2023
Ingresos:	$9.94M
Beneficio Bruto:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2023
Ingresos:	$9.94M
Beneficio Bruto:	$7.68M (77.33 %)
EPS:	$-5.81

FY	2022
Ingresos:	$14.88M
Beneficio Bruto:	$11.91M (80.06 %)
EPS:	$-3.90

FY	2021
Ingresos:	$23.49M
Beneficio Bruto:	$23.49M (100.00 %)
EPS:	$-18.80

Financial Reports:

No articles found.

Syros Pharmaceuticals Inc

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Actualizaciones en tiempo real para Syros Pharmaceuticals Inc [SYRS]

Upcoming Earnings Alert